Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Advances Alefacept To Phase II For Renal Transplant Rejection Prevention

This article was originally published in PharmAsia News

Executive Summary

Taking a step to expand its immunosuppressant pipeline, Astellas is initiating Phase II clinical trials in North America and Europe for its biologic ASP0485 (alefacept) to prevent renal transplant rejection, the firm announced Sept. 12

You may also be interested in...

Astellas Sees Further FDA Action On Prograf MR In Early 2008

Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.

Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 2 0f 2)

Exec talks about emerging markets in Asia, and how Astellas’ culture differs from other Japanese pharmas.

Astellas Buys Amevive From Biogen Idec

Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts